The Develpment of Cancer Day Care Model In the Outpatient setting ; Evidence Based approach

本研究的目的是开发和评估癌症日间护理模式（CDCM）作为一种新的护理系统，帮助癌症患者生活。在研究的最后一年，进行了临床试验，以进一步完善和实际应用该模型。取得了以下成果。（1）经过不断完善，CDCM已发展成为一个实用的护理计划，包括自学材料（如小册子、日志和录像带）和患者支持小组计划。（2）由肿瘤科护士小组和乳腺癌患者组成员检查该程序的相关性和适当性，并进行修改。(3)As在项目实施的准备过程中，我们与研究合作医院的门诊部门合作，以确保项目的安全和有效实施，并为参与项目实施的护士举办了一次教育研讨会。（4）采用准实验设计研究方法对方案效果进行了检验。为了控制外源性变量，受试者仅限于在门诊接受盐酸表吡鲁胺和环磷酰胺术后化疗的乳腺癌患者。为了避免两种样品的数据污染，首先从对照组收集数据。然后，由参加教育工作坊的护士向实验组提供该方案。作为该计划的直接效果，与对照组相比，实验组的抑郁评分显着降低。对于未来的研究，我们建议进一步开发和应用这种CDCM，将更充分地适应更广泛的癌症患者群体的背景和偏好。

The purpose of this research was to develop and evaluate a Cancer Day Care, Model (CDCM) as a new care system which helps patients living with cancer. In this final year of the research, clinical trials were conducted for further refinement and practical application of the model. The following outcomes were obtained. (1)After continual refinement, the CDCM was developed into a practical care program that included self learning materials (e.g. booklets, a log book, and video tapes), and a patients' support group program. (2)The program was examined for its relevance and appropriateness by a panel of oncology nurses, and members of a group of breast cancer patients, and modified. (3)As the preparation of the program operation, we collaborated with the outpatient sector of the research partner hospital for the program would be applied safely and efficiently, and held an educational workshop for nurses involved with the operation of the program. (4)The quasi experimental design research was conducted to test the program effects. To control exogenous variables, subjects were limited to those breast cancer patients receiving postoperative chemotherapy using epirubicin hydrochloride and cyclophosphamide in outpatient setting. To avoid contamination of data from both samples, data were collected first from the control group. Then, the program was provided to the experimental group by the nurses, who attended the educational workshop. As an immediate effect of the program, depression score was significantly reduced for the experimental group compared to the control group. For future research, we recommend further development and application of this CDCM that will more fully accommodate the background and preference of a wider group of cancer patients.